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A BS TR AC T
BACKGROUND
Results of previous single-center, observational studies suggest that daily bathing of 
patients with chlorhexidine may prevent hospital-acquired bloodstream infections 
and the acquisition of multidrug-resistant organisms (MDROs).
METHODS
We conducted a multicenter, cluster-randomized, nonblinded crossover trial to evalu-
ate the effect of daily bathing with chlorhexidine-impregnated washcloths on the 
acquisition of MDROs and the incidence of hospital-acquired bloodstream infec-
tions. Nine intensive care and bone marrow transplantation units in six hospitals 
were randomly assigned to bathe patients either with no-rinse 2% chlorhexidine–
impregnated washcloths or with nonantimicrobial washcloths for a 6-month peri-
od, exchanged for the alternate product during the subsequent 6 months. The inci-
dence rates of acquisition of MDROs and the rates of hospital-acquired bloodstream 
infections were compared between the two periods by means of Poisson regression 
analysis.
RESULTS
A total of 7727 patients were enrolled during the study. The overall rate of MDRO 
acquisition was 5.10 cases per 1000 patient-days with chlorhexidine bathing versus 
6.60 cases per 1000 patient-days with nonantimicrobial washcloths (P = 0.03), the 
equivalent of a 23% lower rate with chlorhexidine bathing. The overall rate of hos-
pital-acquired bloodstream infections was 4.78 cases per 1000 patient-days with 
chlorhexidine bathing versus 6.60 cases per 1000 patient-days with nonantimicro-
bial washcloths (P = 0.007), a 28% lower rate with chlorhexidine-impregnated wash-
cloths. No serious skin reactions were noted during either study period.
CONCLUSIONS
Daily bathing with chlorhexidine-impregnated washcloths significantly reduced 
the risks of acquisition of MDROs and development of hospital-acquired blood-
stream infections. (Funded by the Centers for Disease Control and Prevention and 
Sage Products; ClinicalTrials.gov number, NCT00502476.)
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Multidrug-resistant organisms (MDROs), including methicillin-resis-tant Staphylococcus aureus (MRSA) and 
vancomycin-resistant enterococcus (VRE), have 
become endemic in many acute care and long-
term care facilities.1-5 Infections with these or-
ganisms are often difficult to treat, owing to a 
dwindling armamentarium of active antimicro-
bial agents. The Centers for Disease Control and 
Prevention (CDC) has promulgated a variety of 
strategies, including hand hygiene and the use of 
isolation precautions, to limit the spread of these 
organisms among patients, but these strategies 
require consistent adherence to practices by large 
numbers of health care personnel during fre-
quent patient encounters and can be difficult to 
sustain.6 In addition, health care–associated in-
fections involving these and other microorgan-
isms7,8 are associated with considerable morbidity 
and mortality and with substantial excess costs 
that, in some cases, are no longer reimbursed by 
third-party payers, including the Centers for Medi-
care and Medicaid Services.9,10
Targeted interventions, particularly in inten-
sive care units (ICUs), can substantially reduce the 
risk of hospital-acquired bloodstream infections 
associated with the use of central venous cathe-
ters. Several large studies have shown that im-
proving catheter-insertion processes, including 
standardizing insertion-site antisepsis with the 
use of chlorhexidine-containing products, can 
decrease the risk of infection.11-13 However, the 
use of antiseptic agents for patient bathing is 
currently considered controversial.
Chlorhexidine gluconate is an antiseptic agent 
that has broad-spectrum activity against many 
organisms, including S. aureus and enterococcus 
species. Unlike many other antiseptics, chlor-
hexidine has residual antibacterial activity, which 
may decrease the microbial burden on patients’ 
skin and prevent secondary environmental con-
tamination. Vernon et al. found that daily bath-
ing with chlorhexidine-impregnated cloths de-
creased the number of VRE colonies on skin by 
2.5 log, as compared with bathing with soap 
and water, as well as decreasing VRE contami-
nation of health care workers’ hands by 40% 
and environmental surfaces by 30%.14 By con-
trolling the source, these investigators reduced 
the rate of acquisition of VRE among patients 
by 66%.
Because hospital-acquired bloodstream infec-
tions often result from the ingress of skin organ-
isms into the bloodstream along vascular cath-
eters or other breaks in skin integrity, skin 
decontamination could theoretically also decrease 
the risk of infection. Bleasdale et al. found that 
daily bathing with 2% chlorhexidine–impreg-
nated washcloths reduced the incidence of pri-
mary bloodstream infections by 60%.15 Our 
previous observational study evaluating bathing 
with chlorhexidine in six ICUs showed a 66% 
reduction in VRE bacteremia.16 Previous studies 
of bathing with chlorhexidine have been primar-
ily single-center, before-and-after, observational 
studies, with limited general applicability of re-
sults. We therefore conducted a multicenter, 
randomized trial to evaluate the usefulness of 
bathing with chlorhexidine to reduce the risks of 
MDRO acquisition and hospital-acquired blood-




We performed a cluster-randomized, crossover 
study involving patients hospitalized in six ICUs 
or bone marrow transplantation units between 
August 2007 and February 2009. Units were 
randomly assigned to perform daily bathing of 
patients with either nonantimicrobial wash-
cloths (Comfort Bath, Sage Products) (control) or 
washcloths impregnated with 2% chlorhexidine 
gluconate (2% Chlorhexidine Gluconate Cloth 
Patient Preoperative Skin Preparation, Sage Prod-
ucts) (intervention) during the initial 6-month 
study period, followed by daily bathing with the 
alternate product during the second 6-month 
period.
Bathing was completed according to the man-
ufacturer’s instructions. In brief, washcloths were 
used in sequential order to rinse all body sur-
faces, with the exception of the face during bath-
ing with the 2% chlorhexidine–impregnated 
cloths in order to avoid exposure of the mucous 
membranes of the eyes and mouth. There was 
no washout period in the transition to the new 
product. Infections and MDRO acquisitions were 
monitored for 2 days after the transition and 
assigned to the previous bathing treatment if 
they occurred within that time period.
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The order in which units were assigned to the 
control or intervention period was stratified ac-
cording to unit type and facility. The nine par-
ticipating units were divided into two groups. 
Group 1 (five units) started with bathing with 
the chlorhexidine-impregnated washcloths, fol-
lowed by bathing with nonantimicrobial wash-
cloths. Group 2 (four units) started with bathing 
with nonantimicrobial washcloths, followed by 
bathing with the chlorhexidine-impregnated wash-
cloths. The investigators and clinical staff were 
aware of the use of the control or intervention 
bathing product.
Before the study was initiated, nurses were 
instructed on the proper techniques for bathing 
patients with both washcloth products. Skin-care 
products that were not compatible with chlorhex-
idine were eliminated before the study began. 
Nursing personnel monitored patients for skin 
reactions and reported them to the investigators, 
who graded skin reactions on a scale of 1 to 4 
(with higher numbers indicating greater severity) 
and determined whether the reactions were at-
tributable to bathing (for details of the assess-
ments and scales, see the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org).
All units performed active surveillance testing 
for MRSA and VRE throughout the study period. 
Unit staff obtained swabs from the nares (for 
MRSA) and perirectal area (for VRE) from pa-
tients up to 48 hours after admission to the unit 
and on discharge from the unit. The microbiology 
laboratory at each institution processed surveil-
lance specimens using either standard culture-
based or molecular-based (polymerase chain re-
action) identification of MRSA and VRE. All 
patients found to be colonized or infected with 
MRSA or VRE were placed on contact precautions 
once test results became available. Patients with 
a history of MRSA or VRE colonization or infec-
tion were placed on contact precautions at the 
time of admission.
Each participating unit submitted at least 10 
separate MRSA and VRE isolates obtained from 
patients to the coordinating center each month 
for chlorhexidine susceptibility testing. Suscepti-
bility testing was completed by means of the 
agar dilution method, with chlorhexidine con-
centrations ranging from 0.1 to 1024.0 μg per 
milliliter.17
STUDY OVERSIGHT
Sage Products supplied the chlorhexidine-impreg-
nated and nonantimicrobial washcloths to par-
ticipating units for the duration of the study, pro-
vided technical and educational support, and 
participated in weekly teleconferences with the 
study group during the conduct of the study but 
was not involved in the study design, the data 
analysis, or the preparation of the manuscript. 
Approval of the study protocol was obtained from 
institutional review boards at the study centers 
and the CDC. Waiver of written informed consent 
was obtained at each institution, owing to the 
minimal-risk nature of the study. Patients who 
declined to participate were not bathed with 
chlorhexidine-impregnated washcloths. All au-
thors vouch for the completeness and accuracy 
of the data presented and for the fidelity of 
this report to the study protocol, which is 
available at NEJM.org.
DEFINITIONS
Incident and prevalent cases of MRSA or VRE 
colonization or infection were classified as previ-
ously described.16 Bloodstream infections were 
identified with the use of National Healthcare 
Safety Network definitions.18 Hospital-acquired 
bloodstream infections were defined as blood-
stream infections detected more than 48 hours 
after admission to the unit. Primary bloodstream 
infections were defined as hospital-acquired blood-
stream infections detected more than 48 hours 
after admission to the unit without an attributable 
secondary source of infection. Central-catheter–
associated bloodstream infections were defined 
as primary bloodstream infections in patients 
with at least one central venous catheter in place 
within 48 hours before detection of the infection.
TREATMENT INTERRUPTION
On June 28, 2008, Sage Products initiated a nation-
wide recall of the 2% chlorhexidine–impregnated 
washcloths, because of Burkholderia cepacia con-
tamination of some product lots. Units using the 
chlorhexidine product at the time of the recall were 
switched to the nonantimicrobial washcloths, and 
the institutional review boards were immediately 
notified. After remediation and approval by the 
institutional review boards, use of the chlorhexi-
dine product was resumed. Data from units that 
had been assigned to use the chlorhexidine-based 
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washcloths during the recall period were cen-
sored from the final analysis.
STATISTICAL ANALYSIS
We evaluated changes in the mean rates of MRSA 
and VRE acquisition and hospital-acquired blood-
stream infections. We tested the null hypothesis 
that the rates during the control period equaled 
the rates during the intervention period, using the 
PROC GENMOD procedure in SAS software, ver-
sion 8.2 (SAS Institute), to fit a Poisson regression 
model that accounted for monthly prevalence of 
MRSA and VRE colonizations or infections in 
each unit as possible confounders.
We used a Cox proportional-hazards regression 
model to compare the time from admission until 
the first primary bloodstream infection between 
the control and intervention periods. We calcu-
lated the survival time as the interval between 
admission and discharge from the study unit for 
those patients who did not acquire a primary 
bloodstream infection and as the interval between 
admission and the first positive culture for pa-
tients with a primary bloodstream infection.
We examined the effect of the following unit 
characteristics on the rates of primary bloodstream 
infections: unit size, unit type, mean length of 
stay, rate of use of central venous catheters, me-
dian patient age, distribution of patient sex, 
monthly rate of incident MRSA colonizations or 
infections, monthly rate of incident VRE coloni-
zations or infections, rate of prevalent MRSA 
colonization or infection at the time of admis-
sion, and rate of prevalent VRE colonization or 
infection at the time of admission. We compared 
changes in the rates of incident primary blood-
stream infections between the control period 
and the intervention period. Continuous vari-
ables were examined with the use of two-sample 
t-tests and linear regression modeling, and cat-
egorical variables were examined by means of 
Fisher’s exact test.
R ESULT S
CHARACTERISTICS OF THE STUDY UNITS
Twelve units from seven hospitals were recruited 
to participate in the planned 12-month study. One 
unit withdrew from the study, and two units were 
eliminated from the analysis because of low com-
pliance with the study protocol. The final nine 
study units included medical, coronary care, sur-
gical, and cardiac surgery ICUs and one bone mar-
row transplantation unit (Table 1). Only 8 (0.1%) 
Table 1. Characteristics of the Participating Study Units.*
Hospital Unit
Mean No.  
of Monthly  
Admissions
Mean No.  
of Monthly  
Patient-Days






Baseline Rate of  
Primary Bloodstream 
Infections†
number (range) days percent of admissions no./1000 patient-days
Group 1
A MICU 123.8 (114–142) 692.3 (504–773) 5.6 11.0 21.0 8.1
C SICU 46.3 (31–59) 285.7 (251–314) 6.2 11.4 4.3 9.6
D SICU 2 51.6 (32–71) 285.7 (227–338) 5.5 4.4 2.8 0
E CSICU 85.3 (80–100) 425.9 (375–486) 5.0 6.6 8.3 0.4
F BMT 41.8 (32–58) 786.3 (725–858) 18.8 2.4 21.6 5.5
Group 2
B MICU 111.6 (98–126) 598.8 (449–641) 5.4 21.8 21.0 3.1
C MICU–CCU 55.8 (43–73) 299.1 (211–345) 5.4 16.1 9.7 8.5
D SICU 1 62.3 (47–76) 316.3 (266–356) 5.1 10.8 8.2 2.2
E MICU 72.7 (56–88) 467.1 (404–525) 6.4 23.3 27.9 8.7
* Group 1 used chlorhexidine-impregnated washcloths during the first 6-month period and nonantimicrobial washcloths during the second 
6-month period, and group 2 did the reverse. BMT denotes bone marrow transplantation unit, CSICU cardiac surgery intensive care unit, 
MICU medical intensive care unit, MICU–CCU combined medical intensive care unit and coronary care unit, MRSA methicillin-resistant 
Staphylococcus aureus, SICU surgical intensive care unit, and VRE vancomycin-resistant enterococcus.
† The baseline rate of primary bloodstream infections was defined as the number of new cases among eligible patients during the control period.
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of 7735 patients admitted to the participating 
units declined to participate in the study, and data 
from all 7727 patients who agreed to participate 
were included in an intention-to-treat analysis.
ACQUISITION OF MRSA AND VRE
During the control period, when nonantimicrobial 
cloths were used, 165 new cases of MRSA or VRE 
acquisition were detected, as compared with 127 
during the periods of bathing with chlorhexidine. 
The overall rate of MRSA or VRE acquisition was 
23% lower during the intervention period (5.10 vs. 
6.60 cases per 1000 patient-days, P = 0.03) (Table 2). 
Reductions in the incidence of VRE and MRSA ac-
quisition were unrelated to the monthly prevalence 
of either MRSA or VRE colonization or infection.
The overall rate of VRE acquisition was 25% 
lower during the intervention period than during 
the control period (3.21 vs. 4.28 cases per 1000 
patient-days, P = 0.05). The overall rate of MRSA 
acquisition was 19% lower during the interven-
tion period than during the control period, but this 
difference was not significant (1.89 vs. 2.32 cases 
per 1000 patient-days, P = 0.29).
Table 2. Incidence of Hospital-Acquired Bloodstream Infections and Acquisition of Multidrug Resistant Organisms 
(MDROs), MRSA, and VRE.*
Variable Intervention Period Control Period P Value
No. of admissions 3970 3842 0.32
Total days of care 24,902 24,983 0.85
Central-catheter use (days) 13,425 13,049 0.14
Mean length of stay (days) 6.4 6.4 0.53
MRSA prevalence (%) 13.8 12.8 0.14
VRE prevalence (%) 16.3 15.1 0.24
MDRO acquisition
No. of infections 127 165 0.03
Incidence rate (no./1000 patient-days) 5.10 6.60
VRE acquisition
No. of infections 80 107 0.05
Incidence rate (no./1000 patient-days) 3.21 4.28
MRSA acquisition
No. of infections 47 58 0.29
Incidence rate (no./1000 patient-days) 1.89 2.32
Hospital-acquired bloodstream infection
No. of infections 119 165 0.007
Incidence rate (no./1000 patient-days) 4.78 6.60
Primary bloodstream infection
No. of infections 90 131 0.006
Incidence rate (no./1000 patient-days) 3.61 5.24
Central-catheter–associated bloodstream infection
No. of infections 21 43 0.004
Incidence rate (no./1000 catheter-days) 1.55 3.30
Secondary bloodstream infection
No. of infections 29 34 0.45
Incidence rate (no./1000 patient-days) 1.20 1.40
* Prevalence was defined as the total number of prevalent cases per 100 patients admitted to the study unit. The inci-
dence rate was defined as the total number of acquired cases among eligible patients.
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BLOODSTREAM INFECTIONS
Overall, 165 hospital-acquired bloodstream in-
fections were detected in patients during the 
control period, as compared with 119 during the 
intervention period. The rate of hospital-acquired 
bloodstream infections was 28% lower during the 
intervention period than during the control period 
(4.78 vs. 6.60 cases per 1000 patient-days, P = 0.007) 
(Table 2). This finding reflected the 31% lower 
rate of primary bloodstream infections during the 
intervention period, as compared with the control 
period (3.61 vs. 5.24 cases per 1000 patient-days, 
P = 0.006). The rate of central-catheter–associated 
bloodstream infections was 53% lower during the 
intervention period than during the control pe-
riod (1.55 vs. 3.30 cases per 1000 catheter-days, 
P = 0.004). The rate of secondary bloodstream in-
fections did not differ significantly between the 
intervention and control periods.
On the basis of the Cox proportional-hazards 
survival regression analysis, the risk of acquiring a 
primary bloodstream infection was significantly 
lower among patients bathed with chlorhexidine 
than among those bathed with the nonantimi-
crobial cloths (P = 0.02) (Fig. 1). This effect was 
greater among patients with a longer length of 
stay in the unit. Among patients who were in the 
unit for more than 7 days, the relative risk of a 
primary bloodstream infection was 0.69 (95% con-
fidence interval [CI], 0.47 to 0.99) for patients 
bathed with chlorhexidine as compared with those 
bathed with the nonantimicrobial washcloths. 
Among patients who were in the unit for more 
than 14 days, the relative risk of a primary blood-
stream infection was 0.51 (95% CI, 0.30 to 0.87) 
among patients bathed with chlorhexidine as com-
pared with those who were bathed with the non-
antimicrobial washcloths.
Among the 221 primary bloodstream infec-
tions, the most common pathogens were staphy-
lococci (30%), gram-negative bacilli (23%), en-
terococci (20%), and fungi (13%) (Table 3). The 
incidence rate of primary bloodstream infection 
caused by coagulase-negative staphylococci was 
56% lower during the intervention period than 
during the control period (0.60 vs. 1.36 cases per 
1000 patient-days, P = 0.008). Similarly, the inci-
dence rate of primary bloodstream infection 
caused by fungi was 53% lower during the inter-
vention period than during the control period, 
but this finding was not significant (0.36 vs. 
0.76 cases per 1000 patient-days, P = 0.06).
The incidence of central-catheter–associated 
bloodstream infections was significantly lower 
during the intervention period than during the 
control period for infections involving gram-
positive organisms (0.89 vs. 1.76 cases per 1000 
catheter-days, P = 0.05) and those involving fungi 
(0.07 vs. 0.77 cases per 1000 catheter-days, 
P<0.001). Overall, the incidence of central-cathe-
ter–associated fungal bloodstream infection was 
90% lower during the intervention period than 
during the control period. Bathing with chlorhex-
idine was not associated with a significant reduc-
tion in the incidence of central-catheter–associated 
bloodstream infections involving gram-negative 
organisms or those involving VRE or MRSA, find-
ings that are probably related to the low number 
of infections caused by these organisms.
Owing to concern that the interruption of treat-
ment may have affected the observed outcomes, 
we performed an additional analysis of the inci-


















































































Figure 1. Kaplan–Meier Estimates of Time to Primary Bloodstream Infection.
The cumulative probability of a primary bloodstream infection (BSI) is 
shown for patients who were bathed with chlorhexidine-impregnated wash-
cloths as compared with those who were bathed with nonantimicrobial 
washcloths. The overall protective efficacy of chlorhexidine bathing was 
30%. The inset shows a more detailed version of the larger graph, with a 
cumulative probability of primary BSI of up to 0.25.
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cluded those months when nonantimicrobial 
cloths were used by units affected by the national 
recall. The addition of data obtained during the 
4 months of treatment interruption, when only 
nonantimicrobial bathing cloths were used, did 
not alter the analysis results. In this analysis, 58 
months of use of nonantimicrobial cloths for 
bathing was compared with 54 months of use of 
the 2% chlorhexidine-impregnated cloths. The 
overall results remained the same. The overall 
incidence of hospital-acquired bloodstream in-
fection was decreased in those months when 
chlorhexidine was in use, as compared with the 
use of the nonantimicrobial washcloths (4.78 vs. 
6.32 cases per 1000 patient-days, P = 0.02).
UNIT CHARACTERISTICS
Reductions in rates of primary bloodstream in-
fections were highest among medical ICUs. The 
rate of primary bloodstream infections in medi-
cal ICUs was 40% lower during the intervention 
period than during the control period (3.98 vs. 
6.62 cases per 1000 patient-days). In contrast, the 
rate of primary bloodstream infections in other 
units was 17% lower during the intervention pe-
riod than during the control period (3.10 vs. 3.73 
cases per 1000 patient-days) (Fig. 2). However, the 
observed reductions in the rate of primary blood-
stream infections among medical ICUs were not 
significantly associated with the unit type. Other 
unit characteristics — unit size, mean length of 
stay, baseline rate of primary bloodstream infec-
tions, median age of patients, MRSA and VRE 
prevalence, catheter use, and sex distribution — 
were not associated with changes in the rates of 
primary bloodstream infections.
CHLORHEXIDINE SUSCEPTIBILITY
We performed antimicrobial susceptibility test-
ing on clinical isolates collected during the entire 
Table 3. Etiologic Agents of Identified Primary Bloodstream Infections.*





Staphylococci 24 0.96 42 1.68 0.03
Staphylococcus aureus 9 0.36 8 0.32 0.80
Coagulase-negative staphylococci 15 0.60 34 1.36 0.008
Enterococci 19 0.76 26 1.04 0.30
Enterococcus faecalis 13 0.52 19 0.76 0.29
E. faecium 6 0.24 6 0.24 1.00
Gram-negative bacilli 23 0.92 27 1.08 0.58
Acinetobacter 1 0.04 2 0.08 1.00
Escherichia 8 0.32 6 0.24 0.52
Enterobacter 2 0.08 8 0.32 0.06
Klebsiella 5 0.20 5 0.20 1.00
Pseudomonas 4 0.16 2 0.08 0.41
Serratia 2 0.08 1 0.04 1.00
Stenotrophomonas 0 0.00 1 0.04 1.00
Other 1 0.04 2 0.08 1.00
Fungi 9 0.36 19 0.76 0.06
Candida 7 0.28 16 0.64 0.06
Other 2 0.08 3 0.12 0.66
Polymicrobial organisms 9 0.36 12 0.48 0.52
Other 6 0.24 5 0.20 0.76
Total 90 3.61 131 5.24 0.01
* The incidence rate was defined as the number of primary bloodstream infections per 1000 patient-days.
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study period. We tested a total of 1106 isolates 
(713 MRSA and 393 VRE) for susceptibility to 
chlorhexidine by means of the agar dilution meth-
od. Chlorhexidine was slightly more active against 
MRSA isolates, with a minimum inhibitory con-
centration required to inhibit the growth of 90% 
of organisms of 4 μg per milliliter, as compared 
with 8 μg per milliliter for VRE isolates.
ADVERSE REACTIONS
The overall incidence of skin reactions among 
patients assigned to chlorhexidine bathing was 
2.0% (78 of 3970 patients), as compared with 
3.4% (130 of 3842) among those assigned to 
bathing with the control product. All 208 report-
ed skin reactions were considered to be unrelated 
to the bathing intervention, and overall, 85% of 
the reactions were classified as mild to moderate 
(grade 1 or 2).
DISCUSSION
The findings of this multicenter, cluster-random-
ized study evaluating daily bathing with chlorhex-
idine support the results of previous single-center 
trials suggesting that bathing with chlorhexidine 
reduces the transmission of resistant organisms 
and the risk of hospital-acquired bloodstream in-
fections among patients in ICUs and bone mar-
row transplantation units.14-16,19,20 In addition, the 
participation of facilities from different geograph-
ic regions in the United States supports the gen-
eralizability of these results to other academic 
medical centers.
Our results support the findings of Vernon et 
al. and Bleasdale et al. and suggest that bathing 
with chlorhexidine may be particularly effective 
in reducing the risk of bloodstream infections 
among patients in the ICU.14,15 In contrast to 
these previous studies, which involved a limited 
number of units, our multicenter design allowed 
a more robust examination of whether the re-
ductions in rates of bloodstream infections were 
related to the type of unit. We found no signifi-
cant interaction between the type of unit and the 
development of bloodstream infections, suggest-
ing that bathing with chlorhexidine may be 
beneficial in many unit settings. In addition, 
bathing with chlorhexidine may be particularly 
beneficial for patients with long ICU stays.
Our study also had some unanticipated find-
ings. First, as compared with bathing with the 
control product, bathing with chlorhexidine was 
associated with lower rates of central-catheter–
associated fungal bloodstream infection. Previ-
ous studies have shown that bathing with 
chlorhexidine is associated with a lower risk of 
central-catheter–associated bloodstream infec-
tion involving gram-positive cocci,14-16 but re-
duced rates of fungemia have not been reported. 
Chlorhexidine has biphasic fungicidal activity,21 
but topical use has not been suggested as a pos-
sible intervention to reduce the incidence of funge-
mia among patients with indwelling central 
catheters. Previous efforts to reduce the incidence 
of fungemia have relied mostly on systemic an-
tifungal prophylaxis, which can increase the in-
cidence of antifungal resistance among fungal 
isolates.22 If our results are confirmed, topical 
use of chlorhexidine could be added to strategies 
to prevent fungal infections.
Bathing with chlorhexidine was associated 
with significant reductions in the incidence of 
gram-positive bacteremias, findings that are 
similar to the results of previous studies. The 
majority of these reductions were related to the 
reductions in the incidence of infections involv-
ing coagulase-negative staphylococci. Despite 





























Figure 2. Rates of Primary Bloodstream Infections 
According to the Type of Hospital Unit.
Incidence rates of hospital-acquired primary blood-
stream infections are shown among units using daily 
bathing with either chlorhexidine-impregnated wash-
cloths or nonantimicrobial washcloths (control). BMT 
denotes bone marrow transplantation unit, MICU 
medical intensive care unit, and SICU surgical inten-
sive care unit.
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and VRE, significant reductions in the incidence 
of MRSA and VRE bacteremias were not seen. 
This was probably related to the overall low num-
ber of hospital-acquired bacteremias due to these 
two organisms.
We did not identify any serious adverse ef-
fects of daily bathing with the chlorhexidine-
impregnated washcloths. Serious allergic reac-
tions have been reported with the topical use of 
chlorhexidine, but these reactions appear to be 
rare.23-26 We did not detect the emergence of 
MRSA or VRE isolates with high-level resistance 
to chlorhexidine during the study. Concern regard-
ing increased resistance of nosocomial bacteria 
to biocides and disinfectants like chlorhexidine 
has tempered enthusiasm for wider adoption of 
their use in hospitals for skin antisepsis.27-34 The 
potential for the emergence of resistance to 
chlorhexidine remains a substantial concern and 
should be monitored over time.35
Identifying simple, cost-effective, and safe strat-
egies for the prevention of health care–associated 
infection is essential. Daily bathing with chlorhex-
idine-impregnated washcloths is a strategy that 
is relatively straightforward to implement and 
sustain because it does not require a substantial 
change from patient-bathing practices that are 
currently routine. We found that this intervention 
was associated with reductions in the rates of 
MRSA and VRE acquisition and hospital-acquired 
bloodstream infection.
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